The strong Q2 beat and balance sheet cleanup (convertible note redemption, deferred tax asset recognition) mark a fundamental inflection point. Traders should watch for the EU MAA decision on YUVIWEL in Q4 2026 as a key catalyst. The COACH combination therapy data supports a potential expansion of the achondroplasia market opportunity. Monitor SG&A trajectory for margin expansion as the commercial infrastructure scales.
Price Chart
Executive Summary
Ascendis Pharma reported a transformative Q2 2026 with revenue surging to EUR 339.3M (up 115% YoY) driven by YORVIPATH growth and the YUVIWEL launch, generating a net profit of EUR 207.0M vs a loss of EUR 38.9M a year ago. The company also recognized a EUR 679.6M deferred tax asset and sold a Priority Review Voucher for $187.5M, while fully redeeming its $575M convertible notes via equity conversion, strengthening the balance sheet. The strong commercial execution and pipeline progress (COACH combination therapy data, EU MAA decision for YUVIWEL expected Q4 2026) support a bullish outlook, though elevated SG&A costs from commercial expansion and ongoing IP litigation with BioMarin are risks to monitor.
Key Facts
- Q2 2026 revenue of EUR 339.3M, up 115% YoY from EUR 158.0M
- YORVIPATH revenue of EUR 252.1M in Q2 2026, up 145% YoY from EUR 103.0M
- YUVIWEL (navepegritide) launched in the U.S. in Q2 2026, contributing EUR 7.6M in revenue
- Net profit of EUR 207.0M in Q2 2026 vs net loss of EUR 38.9M in Q2 2025
- Recognized EUR 679.6M deferred tax asset in H1 2026, reflecting improved profitability outlook
- Sold Rare Pediatric Disease Priority Review Voucher for $187.5M, netting EUR 158.1M in other operating income
- Fully redeemed $575M 2.25% convertible notes due 2028 via equity conversion on May 6, 2026, eliminating debt and derivative liabilities
- Cash and cash equivalents of EUR 812.3M as of June 30, 2026, up from EUR 616.0M at year-end 2025
- COACH combination therapy (TransCon CNP + TransCon hGH) showed sustained growth at Week 78, with 100% retention
- EU MAA decision for YUVIWEL (navepegritide) expected in Q4 2026
Financial Impact
Revenue more than doubled YoY to EUR 339.3M (Q2) and EUR 585.9M (H1). Net income swung from a loss of EUR 38.9M to a profit of EUR 207.0M in Q2. The balance sheet was strengthened by EUR 719.5M in equity from convertible note conversion and a EUR 699.3M deferred tax asset.
Risk Factors
- Ongoing IP litigation with BioMarin regarding TransCon CNP (YUVIWEL) in the U.S. (ITC) and other jurisdictions could create overhang
- Elevated SG&A expenses (EUR 318.6M in H1 2026) from commercial expansion may pressure margins if revenue growth decelerates
- EU MAA decision for YUVIWEL in Q4 2026 is binary and could impact ex-U.S. revenue expectations
- Tariff uncertainty on pharmaceutical imports could impact supply chain costs
- Foreign exchange risk from USD-denominated revenue and EUR reporting currency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001612042-26-000016 |
| Document: 0001612042-26-000016-index-headers.html | 0001612042-26-000016 |
| Document: 0001612042-26-000016-index.html | 0001612042-26-000016 |
| Document: 0001612042-26-000016.txt | 0001612042-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access